Capital Fund Management S.A. Has $14.17 Million Stock Position in Natera, Inc. $NTRA

Key Points

• Capital Fund Management S.A. reduced its stake in Natera, Inc. by 25.2%, selling 33,680 shares and owning about 0.07% of the company post-sale.
• Recent analyst reports show a consensus rating of "Buy" for Natera, with price targets ranging from $170.00 to $220.00.
• Natera reported a loss of ($0.74) EPS in its latest earnings, missing estimates, despite a revenue increase of 32.2% year-over-year.

Capital Fund Management S.A. trimmed its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 25.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 100,171 shares of the medical research company's stock after selling 33,680 shares during the period. Capital Fund Management S.A. owned approximately 0.07% of Natera worth $14,165,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of NTRA. Price T Rowe Associates Inc. MD boosted its holdings in Natera by 134.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock valued at $1,067,327,000 after acquiring an additional 3,871,862 shares during the period. Nuveen LLC bought a new stake in Natera during the first quarter valued at about $113,375,000. JPMorgan Chase & Co. boosted its holdings in Natera by 9.9% during the first quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock valued at $1,041,055,000 after acquiring an additional 660,538 shares during the period. SG Americas Securities LLC boosted its holdings in Natera by 8,233.5% during the first quarter. SG Americas Securities LLC now owns 397,924 shares of the medical research company's stock valued at $56,270,000 after acquiring an additional 393,149 shares during the period. Finally, Invesco Ltd. boosted its holdings in Natera by 13.7% during the first quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company's stock valued at $287,908,000 after acquiring an additional 245,719 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Wall Street Zen cut shares of Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Stephens reissued an "overweight" rating and issued a $183.00 price target on shares of Natera in a report on Friday, August 15th. Cowen reissued a "buy" rating on shares of Natera in a report on Friday, August 8th. Barclays reissued an "overweight" rating and issued a $210.00 price target (up from $190.00) on shares of Natera in a report on Friday, August 8th. Finally, Morgan Stanley reissued an "overweight" rating and issued a $195.00 price target on shares of Natera in a report on Sunday, August 10th. One investment analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $193.19.

Natera Stock Performance

Shares of NASDAQ:NTRA traded up $3.65 during midday trading on Friday, reaching $165.60. 839,847 shares of the company's stock were exchanged, compared to its average volume of 1,655,524. The company's 50 day simple moving average is $154.85 and its two-hundred day simple moving average is $154.16. The firm has a market capitalization of $22.73 billion, a PE ratio of -86.70 and a beta of 1.76. Natera, Inc. has a 12 month low of $110.57 and a 12 month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The business had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.Natera's revenue was up 32.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Buying and Selling at Natera

In other news, CEO Steven Leonard Chapman sold 6,111 shares of the firm's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $157.10, for a total transaction of $960,038.10. Following the completion of the transaction, the chief executive officer directly owned 179,071 shares of the company's stock, valued at approximately $28,132,054.10. This trade represents a 3.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael Burkes Brophy sold 3,045 shares of the firm's stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total transaction of $418,383.00. Following the transaction, the chief financial officer directly owned 65,430 shares of the company's stock, valued at $8,990,082. The trade was a 4.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 61,792 shares of company stock valued at $9,227,972 over the last quarter. 5.63% of the stock is currently owned by insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.